Purpose: To observe the effect of different high-dose-rate (HDR) intracavitary brachytherapy dose schedules on equieffective dose in 2 Gy per fraction (EQD 2 ).
Purpose
Cervical cancer is the fourth most common cancer among women in terms of incidence and mortality [1] . Majority of patients present in locally advanced stage, and need external beam radiotherapy (EBRT) and brachytherapy (BT) as well as concurrent chemotherapy. Brachytherapy plays an important role in the treatment of cervical cancer. Low-dose-rate (LDR) brachytherapy is replaced by high-dose-rate (HDR) brachytherapy, which is more convenient for patient, with no risk of radiation exposure to the staff and most importantly, with the advantage of dose optimization [2] . Most of the institutes follow similar dose prescription pattern for LDR brachytherapy; however, there is a wide range of discrepancy in HDR brachytherapy dose prescription. In the literature, we have observed different institutions following different HDR brachytherapy schedules such as 5.5 Gy × 5 fractions, 6 Gy × 4 fractions, 7 Gy × 3 fractions, and 9 Gy × 2 fractions, probably because of the availability of the resources and logistic problems. In our institute, we follow 6.5 Gy × 4 fractions for two consecutive days, after 45 Gy EBRT. Since the local control and toxicities are determined by the dose per fraction, it is important to know the EQD 2 for different dose prescription schedules for HDR brachytherapy. EQD 2 or equieffective dose is also referred as equivalent dose in 2 Gy fractions [1, 3, 4, 5, 6] .
The aim of this work is to investigate different HDR brachytherapy dose schedules of EQD 2 for highrisk clinical target volume (CTV HR ) and organs at risk (OARs), and also comparing dose schedules with available literature.
Material and methods
In this retrospective study, cervical cancer patients with stage IB2 to IIB treated from January 2017 to December 2017 were included. Fifty patients who underwent intracavitary brachytherapy (ICBT) were included, and patients who underwent combination of ICBT with interstitial needles were excluded from the study.
Procedure
Around 10-15 days after the completion of EBRT, ICBT applicators (uterine tandem with flange and two vaginal ovoids) were inserted under spinal anesthesia or mild sedation. To ensure the emptiness of the rectum, sodium phosphate enema was given two hours before the procedure. Computed tomography (CT) scan simulation without intravenous contrast was completed after the insertion of applicators. During CT simulation, bladder was filled with 50 ml of normal saline and rectum was filled with 20 ml of rectal contrast. Axial CT slices of 3 mm thickness were taken from the upper border of third lumbar vertebra to the middle of shaft of the femur. The CT images were transferred to treatment planning system (HDR Plus, Bebig, Eckert and Ziegler, Germany) compliant with the Task Group 43 (TG-43) algorithm.
Planning and evaluation
The OARs such as bladder, rectum, sigmoid, and CTV HR were contoured according to the guidelines published by Viswanathan et al. [7] . CTV HR was defined based on the findings of examination under anesthesia and CT scan image. Intermediate-risk clinical target volume (CTV IR ) was created by giving 10 mm margin to CTV HR . Applicators were digitized using the applicator library and verified with digitally reconstructed radiograph (DRR) before activating the dwell positions. At that point, CTV HR surface control points were generated and dose prescribed to CTV HR . The dose-volume histogram (DVH) parameters were evaluated and isodose reshaper tool was used to maintain the pear shape dose distribution with maximum possible D 90 (dose received by 90% of the CTV HR ) and restrict the dose to OARs within the permissible limits. Figure 1 shows the dose distribution of intracavitary brachytherapy. Even though the dose was prescribed to CTV HR , we also calculated the dose received by point A, which was marked 2 cm superior to external os and 2 cm perpendicular to the uterine tandem.
Dosimetric details
Four different plans were generated for each patient, with dose prescriptions of 5.5 Gy × 5 fractions (plan A), 6.5 Gy × 4 fractions (plan B), 7 Gy × 4 fractions (plan C), and 9 Gy × 2 fractions (plan D) to CTV HR . The EQD 2 for 0.1 cm 3 and 2 cm 3 of bladder, rectum, sigmoid, point A, and D 90 were calculated for all plans, using the formula
where n is the number of fractions and d is the dose per fraction. The α/β ratio was considered as 3 for normal tissues and 10 for the tumor [8] . The values were tabulated and analyzed by the statistical software SPSS version 18.0 (SPSS Inc., IBM, Chicago, USA). One-way ANOVA test was used to compare the values. The values were considered to be statistically significant when p ≤ 0.05.
Results
A total of two hundred plans were generated for different dose prescriptions. The mean EQD 2 for OARs, D 90 CTV HR , and point A is summarized in Tables 1 and 2 
Discussion
This retrospective dosimetric study was conducted to compare 6.5 Gy × 4 fractions of ICBT that we follow with the other fractionation schedules available in the literature. An attempt was made to compare the EQD 2 of D 90 CTV HR and OARs. In the literature, we found different dose schedules like 5 Gy × 5 fractions, 6 Gy × 4 fractions, 7 Gy × 4 fractions, 7.5 Gy × 3 fractions, and 9 Gy × 2 fractions being applied in practice [9, 10, 11, 12, 13, 14, 15, 16] . The choice of fractionation schedule of a particular oncology center mainly depends on the number of patients, availability of the staff, cost effectiveness, etc. At our center, we follow single application of ICBT with four fractions of 6.5 Gy, with 6-hour gap between the fractions, on two consecutive days, two weeks after the completion of EBRT of 45 Gy in 25 fractions by 3DCRT technique, along with concurrent chemotherapy. Image-guided intensity modulated external beam radiochemotherapy and MRIbased adaptive brachytherapy in locally advanced cervical cancer (EMBRACEII) study recommends MRI-based brachytherapy for better delineation of OARs and CTV HR [7, 9] . In our institute, we practice CT-based brachytherapy because of limitation of the resources. We have summarized the EQD 2 of OARs and D 90 CTV HR of different studies in Table 3 . In these studies, the EQD 2 for 2 cm 3 of bladder, 2 cm 3 of rectum, and 2 cm 3 of sigmoid are in the range of 79.7-88.2 Gy, 57.5-82.8 Gy, and 61-73.9 Gy, respectively. According to the ICRU 89 and the American Brachytherapy Society (ABS), the recommended EQD 2 for 2 cm 3 of bladder and rectum is ≤ 90 Gy and ≤ 75 Gy, respectively, and it is also recommended to achieve 85 Gy EQD 2 for D 90 CTV HR [3, 4] . In the present study, the range of EQD 2 for 2 cm 3 of bladder, 2 cm 3 of rectum, and 2 cm 3 of sigmoid is 68.58-77.27 Gy, 64.82-71.11 Gy, and 52.14-55.44 Gy, respectively. Although volume-based prescription is the standard practice, most of the centers still follow the X-ray-based point A prescription. Ghosh et al. in their study based on X-ray-based planning observed higher incidence of late toxicities of bladder and rectum in patients treated with 9 Gy × 2 fractions compared to 7 Gy × 3 fractions [16] . Mazeron et al. reported increased grade 3 and higher rectal complications for dose > 75 Gy for 2 cm 3 of rectum [17] . Georg et al. reported in their study that there is an increased probability of grade 3 rectal toxicities for dose greater than 88 Gy and 76 Gy for 0.1 cm 3 and 2 cm 3 of the rectum, respectively [18] . In a retrospective study by Manir et al. on correlation of rectal toxicity and dose, it was recommended to restrict the dose between 75 to 81 Gy for 0.1 cm 3 of the rectum and between 64 to 69 Gy for 2 cm 3 of the rectum to avoid grade 3 proctitis [19] . In our study, we have observed EQD 2 in the range of 80 to 89 Gy for 0.1 cm 3 of the rectum and 65 to 71 Gy for 2 cm 3 of the rectum by all the four plans. All the dose fractionation schedules were in compliance with the ICRU 89 recommendation for OARs. [12, 22] . In future, we plan to adopt MRI-based brachytherapy for cervical cancer.
Conclusions
EQD 2 of bladder, rectum, sigmoid, D 90 CTV HR , and point A is similar with dose fractionation schedule such as 5.5 Gy × 5 fractions, 6.5 Gy × 4 fractions, and 7 Gy × 4 fractions. EQD 2 of 9 Gy × 2 fractions was significantly unfavorable compared to other schedules. Since it is a dosimetric study, further clinical studies are suggested to analyze the clinical outcome.
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